/SPRY
SPRY Stock - ARS Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$10.49+6.82%
+$0.67 (+6.82%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.42
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.88
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+195.5%upside
Target: $31.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SPRY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$10.39 – $10.59
TARGET (TP)$31.00
STOP LOSS$9.65
RISK/REWARD1:24.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.80
52W High$18.90
52W Low$6.66
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $89.15M | $30,000 | $1.32M | $5.51M | $17.84M |
| Gross Profit | $68.59M | $30,000 | $1.32M | $5.29M | $3.77M |
| Gross Margin | 76.9% | 100.0% | 100.0% | 96.1% | 21.1% |
| Operating Income | $-3,083,000 | $-67,520,000 | $-35,516,000 | $-19,454,000 | $-469,000 |
| Net Income | $8.00M | $-54,365,000 | $-34,682,000 | $-20,243,000 | $-1,065,000 |
| Net Margin | 9.0% | -181216.7% | -2635.4% | -367.7% | -6.0% |
| EPS | $0.08 | $-0.57 | $-0.87 | $-0.70 | $-0.03 |
Company Overview
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
1
8%
Buy / Outperform
11
92%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
12 Bullish0 Neutral/Bearish
Price Targets
$24
Average Target
↑ 124.5% Upside
Now
$10
Low
$24
Average
$40
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 4th 2025 | Roth Capital | Resumed | Buy | $30 |
| September 4th 2025 | Roth Capital | Initiation | Buy | $40 |
| March 7th 2025 | Scotiabank | Initiation | Sector Outperform | $30 |
| February 10th 2025 | Oppenheimer | Initiation | Outperform | $40 |
| August 20th 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
| August 13th 2024 | Raymond James | Upgrade | Strong Buy | $22← $18 |
| August 12th 2024 | Leerink Partners | Reiterated | Outperform | $20← $19 |
| July 25th 2024 | Raymond James | Initiation | Outperform | $18 |
| March 5th 2024 | Leerink Partners | Upgrade | Outperform | $18← $6 |
| February 20th 2024 | William Blair | Upgrade | Outperform | - |
| September 20th 2023 | William Blair | Downgrade | Market Perform | - |
| January 31st 2023 | Wedbush | Initiation | Outperform | $10 |
| January 3rd 2023 | William Blair | Initiation | Outperform | $17 |
| December 13th 2022 | SVB Leerink | Initiation | Outperform | $14 |
Earnings History & Surprises
SPRYBeat Rate
39%
Last 18 quarters
Avg Surprise
+110.8%
EPS vs Estimate
Beats / Misses
7/9
2 met exactly
Latest EPS
$-0.52
Q4 2025
EPS Surprise History
Q1 24
+50.0%
$-0.07vs$-0.14
Q2 24
0.0%
$-0.11vs$-0.11
Q3 24
-8.3%
$-0.13vs$-0.12
Q4 24
-11.1%
$-0.20vs$-0.18
Q1 25
+1400.0%
$0.52vs$-0.04
Q2 25
0.0%
$-0.35vs$-0.35
Q3 25
-12.2%
$-0.46vs$-0.41
Q4 25
-15.6%
$-0.52vs$-0.45
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.41 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.45 | $-0.52 | -15.6% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.41 | $-0.46 | -12.2% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.35 | $-0.35 | 0.0% | = MET |
Q1 2025 | Mar 20, 2025 | $-0.04 | $0.52 | +1400.0% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.18 | $-0.20 | -11.1% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-0.12 | $-0.13 | -8.3% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.11 | $-0.11 | 0.0% | = MET |
Q1 2024 | Mar 21, 2024 | $-0.14 | $-0.07 | +50.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.17 | $-0.18 | -5.9% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.17 | $-0.16 | +5.9% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.13 | $0.77 | +692.3% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.35 | $-0.50 | -42.9% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.48 | $-0.55 | -14.6% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.54 | $-0.70 | -29.6% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-0.70 | $-0.67 | +4.3% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.67 | $-0.65 | +3.0% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.53 | $-0.70 | -32.1% | ✗ MISS |
Latest News
ARS Pharmaceuticals Q3 EPS $(0.52) Misses $(0.47) Estimate, Sales $32.501M Beat $28.743M Estimate
➖ NeutralBenzinga•Nov 10, 2025, 11:00 AM
ARS Pharmaceuticals Launches Get Neffy On Us Commercial Program
📈 PositiveBenzinga•Nov 4, 2025, 01:04 PM
ARS Pharmaceuticals Announces Opposition Division Of The European Patent Office Upholds Nasal Spray Epinephrine Patent
📈 PositiveBenzinga•Oct 8, 2025, 02:14 PM
ARS Pharmaceuticals Secures Up To $250M Loan Facility With RA Capital Management And OMERS Life Sciences For Neffy Commercialization
📈 PositiveBenzinga•Sep 29, 2025, 08:07 PM
ARS Pharma rises after Japan nod for neffy nasal spray for allergy
📈 PositiveSeeking Alpha•Sep 19, 2025, 12:34 PM
ARS Pharma Japanese Authority PMDA Grants Approval For Neffy 1 Mg And 2 Mg Doses, For Emergency Treatment Of Allergic Reactions In Adults And Children
📈 PositiveBenzinga•Sep 19, 2025, 12:02 PM
ARS Pharma Shares Real-World Evidence Evaluating Clinical Performance Of Neffy In Patients Experiencing Anaphylaxis Symptoms During Oral Food Challenge And Allergen Immunotherapy
📈 PositiveBenzinga•Sep 8, 2025, 12:03 PM
Roth Capital Initiates Coverage On ARS Pharmaceuticals with Buy Rating, Announces Price Target of $40
📈 PositiveBenzinga•Sep 4, 2025, 05:46 PM
ARS Pharma drops 9% as Lupin files application for generic neffy
📉 NegativeSeeking Alpha•Aug 29, 2025, 04:04 PM
Frequently Asked Questions about SPRY
What is SPRY's current stock price?
ARS Pharmaceuticals, Inc. (SPRY) is currently trading at $10.49 per share. The stock has moved +6.82% today.
What is the analyst price target for SPRY?
The average analyst price target for SPRY is $31.00, based on 1 analyst.
What sector is ARS Pharmaceuticals, Inc. in?
ARS Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SPRY's market cap?
ARS Pharmaceuticals, Inc. has a market capitalization of $1.03 billion, making it a small-cap company.
Does SPRY pay dividends?
No, ARS Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABUS
Arbutus Biopharma Corporation
$4.43
Mkt Cap: $0.9B
GHRS
GH Research PLC
$12.96
Mkt Cap: $0.8B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
LENZ
LENZ Therapeutics, Inc.
$18.00
Mkt Cap: $0.5B
NBTX
Nanobiotix S.A.
$22.13
Mkt Cap: $1.1B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
PVLA
Palvella Therapeutics, Inc.
$99.73
Mkt Cap: $1.2B
RZLT
Rezolute, Inc.
$1.77
Mkt Cap: $0.2B
SVRA
Savara Inc.
$6.05
Mkt Cap: $1.2B
TYRA
Tyra Biosciences, Inc.
$25.51
Mkt Cap: $1.4B
Explore stocks similar to SPRY for comparison